News
Asahi Kasei Pharma begins phase III study of promising CIPN prevention therapy, Recomodulin to enhance treatment options worldwide: Chelmsford, Massachusetts Thursday, July 3, 202 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback